CD19 CAR-T initially approved for treatment of relapsed/refractory B-cell acute lymphocytic leukemia, are now the standard of care for patients with aggressive non-Hodgkin lymphoma who have progressed after first-line therapy [2–6]. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.